KimHYLeeHJChangYJPichavantMShoreSAFitzgeraldKAet alInterleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity
The study reviewed 79 websites offering compounded GLP-1 receptor agonists like semaglutide and tirzepatide and found notable transparency issues: Compounded drugs are often produced during shortages of brand-name medications but lack FDA oversight for safety and efficacy
None of the sites and social media adverts viewed by the listed all the known side effects of the drug and some claimed that the drug could help reduce risk of skin cancer resulting from sun exposure
The nurse, Abby, administering the IV was skilled and gentle, minimizing any discomfort
In 2023, the FDA approved tirzepatide for obesity, which, according to Gratzl and colleagues, contributed to an increase in prescribing trends of GLP-1 medications
* Autoship only available in the US Why Autoship